King's College London, London, UK.
King's Health Partners Cancer Research UK Centre, London, UK.
Br J Haematol. 2019 Apr;185(1):89-92. doi: 10.1111/bjh.15749. Epub 2019 Jan 13.
Mesenchymal stromal cells (MSCs) have been successfully used for the treatment of steroid-resistant graft-versus-host-disease (GvHD). However, the lack of early predictors of clinical responses impacts on the time at which to add further treatment and consequently the design of informative clinical trials. Here, we present the UK experience of one of the largest cohorts of GvHD patients undergoing MSC infusions so far reported. We show that clinical responses assessed as early as 1 week after MSC infusion predict patients' overall survival. In our cohort, cell dose, patients' age and type of organ involvement are crucial factors associated with clinical responses.
间充质基质细胞 (MSCs) 已成功用于治疗类固醇耐药的移植物抗宿主病 (GvHD)。然而，缺乏对临床反应的早期预测因子会影响何时添加进一步的治疗，从而影响有意义的临床试验的设计。在这里，我们介绍了迄今为止报告的最大 GvHD 患者 MSC 输注队列之一的英国经验。我们表明，MSC 输注后最早 1 周评估的临床反应可预测患者的总生存。在我们的队列中，细胞剂量、患者年龄和器官受累类型是与临床反应相关的关键因素。
